000147242 001__ 147242
000147242 005__ 20241216115436.0
000147242 0247_ $$2doi$$a10.1139/bcb-2024-0153
000147242 0248_ $$2sideral$$a140941
000147242 037__ $$aART-2024-140941
000147242 041__ $$aeng
000147242 100__ $$0(orcid)0000-0002-8467-0356$$aBuey, Berta$$uUniversidad de Zaragoza
000147242 245__ $$aNeuroprotective effects of whey and buttermilk-based formulas on a DSS-induced colitis murine model
000147242 260__ $$c2024
000147242 5060_ $$aAccess copy available to the general public$$fUnrestricted
000147242 5203_ $$aInflammatory bowel disease is a gut–brain axis disorder that comprises chronic inflammatory conditions affecting the gastrointestinal tract, where alterations in the mood of patients are common. Gut–brain axis is a bidirectional communication that link gut and brain. The close association between inflammatory bowel disease and neuroinflammation has far-reaching implications, as is increasingly recognized as a contributing factor to neuropsychiatric and neurodegenerative diseases. The increasing prevalence and high economic cost, together with the loss of life quality of people suffering from these diseases, point to the need to find alternatives to alleviate them. Exploring new therapeutic avenues prompts us to consider the potential benefits of milk fractions, taking advantage of the use of dairy by-products, such as whey and buttermilk. This study examines the impact of cow’s whey- and buttermilk-based formulas supplemented with bovine lactoferrin and milk fat globule membrane on the expression of cytokines, as well as on the components of immune and serotonergic system of the brain in a murine model of dextran sodium sulfate-induced colitis. Our results show the potential of these dairy by-products, especially whey, as functional foods in ameliorating neuroinflammation and safeguarding the central nervous system function amid the neurological complications induced or concomitant with intestinal inflammatory processes.
000147242 536__ $$9info:eu-repo/grantAgreement/ES/DGA/A20-20R$$9info:eu-repo/grantAgreement/ES/DGA/A20-23R$$9info:eu-repo/grantAgreement/ES/MINECO/AGL2017-82987
000147242 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000147242 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000147242 700__ $$0(orcid)0000-0002-5797-3909$$aLatorre, Eva$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0001-8584-3979$$aCastro, Marta$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0002-2231-7565$$aValero, Marta Sofía$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0002-7412-2073$$aPlaza, Miguel Ángel$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0002-2114-0577$$aArruebo, María Pilar$$uUniversidad de Zaragoza
000147242 700__ $$aAbad, Inés$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0002-2685-1730$$aRodríguez-Largo, Ana
000147242 700__ $$0(orcid)0000-0001-5964-823X$$aSánchez, Lourdes$$uUniversidad de Zaragoza
000147242 700__ $$0(orcid)0000-0003-4758-3998$$aMesonero, José Emilio$$uUniversidad de Zaragoza
000147242 7102_ $$11001$$2025$$aUniversidad de Zaragoza$$bDpto. Anatom.,Embri.Genét.Ani.$$cÁrea Anatom.Anatom.Patológ.Com
000147242 7102_ $$11012$$2410$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Fisiología
000147242 7102_ $$11002$$2050$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Biología Celular
000147242 7102_ $$12008$$2780$$aUniversidad de Zaragoza$$bDpto. Produc.Animal Cienc.Ali.$$cÁrea Tecnología de Alimentos
000147242 773__ $$pBiochem. cell. biol.$$tBIOCHEMISTRY AND CELL BIOLOGY-BIOCHIMIE ET BIOLOGIE CELLULAIRE$$x0829-8211
000147242 8564_ $$s1947068$$uhttps://zaguan.unizar.es/record/147242/files/texto_completo.pdf$$yPostprint
000147242 8564_ $$s1126929$$uhttps://zaguan.unizar.es/record/147242/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000147242 909CO $$ooai:zaguan.unizar.es:147242$$particulos$$pdriver
000147242 951__ $$a2024-12-16-11:28:02
000147242 980__ $$aARTICLE